Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2008

View Archived Issues

New therapeutic approach against toxoplasmosis reported

MicroRNA mimics suppress Bcr-Abl expression in vitro and in vivo

Phase II trial of Hsp90 inhibitor alvespimycin begins in HER2+ metastatic breast cancer

Data support therapeutic role for buprenorphine in neuropathic pain

Allon initiates phase I clinical trial of AL-108 and AL-208

Three Rivers acquires hepatitis C drug Infergen from Valeant

Vasopressin V2 receptor agonists prepared and tested at Kissei

Roche responds to the results of the IDEAL hepatitis C trial reported

Upstream enters agreement with MSU for drug candidates for tropical parasitic diseases

FDA grants approval to DAKO to market the TOP2A FISH pharmDx breast-cancer test

Gabriel Sciences receives grant from NIH for development of lead antidepressant compound

Alfacell licenses U.S. commercial rights to Onconase to Strativa Pharmaceuticals

Taranabant induces weight loss in obese subjects

Novartis Pharma and Mitsubishi Tanabe revise agreement for Lochol for hypercholesteremia

Genzyme enters license agreement with Moffitt Cancer Center for lung cancer diagnostic

Tolerx receives payment from Genentech following phase Ib clinical study of TRX-1

Anthera reports positive preliminary results from phase IIb clinical trial of A-002

Celsion to proceed with phase II pivotal breast cancer trial

Protox Therapeutics commences phase IIa PRX-302 trial in prostate cancer

Summit's lead drug candidate, SMT-D001, enters phase II clinical trials

Recent patents describe novel analgesic agents

Remicade label enhancement receives E.U. approval in Crohn's disease

E.U. marketing authorization granted for GSK's Avamys for allergic rhinitis therapy

E.C. grants Remicade label enhancement for ankylosing spondylitis and psoriatic arthritis

New oncolytic drugs described in recent patents

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...